References
1. Subbiah RN, Gula LJ, Skanes AC, et al. Andersen-Tawil syndrome:
Management challenges during pregnancy, labor, and delivery. J
Cardiovasc Electrophysiol . 2008; 19(9):987-9
2. Fox DJ, Klein GJ, Hahn A, et al. Reduction of complex ventricular
ectopy and improvement in exercise capacity with flecainide therapy in
Andersen-Tawil syndrome. Europace . 2008;10(8):1006-8.
3.
Pellizzón
OA, Kalaizich
L, Ptácek
LJ, et al. Flecainide Suppresses Bidirectional Ventricular Tachycardia
and Reverses Tachycardia-Induced Cardiomyopathy in Andersen-Tawil
Syndrome. J Cardiovasc Electrophysiol. 2007;19(1):95-7.
4. Anneken L, Baumann S, Vigneault P, et al. Estradiol regulates human
QT-interval: Acceleration of cardiac repolarization by enhanced KCNH2
membrane trafficking. Eur Heart J . 2016;37(7):640-50.
5. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of
β-blocker therapy in congenital long- QT syndrome. Circulation .
2000;101(6):616-23.
6. Brembilla-perrot B, Amor M, Auque F, et al. Effect of flecainide on
left ventricular ejection fraction. Eur Heart J.1987;8(7):754–61.
7. Van Ert HA, McCune EC, Orland KM, et al. Flecainide treats a novel
KCNJ2 mutation associated with Andersen-Tawil syndrome. Hear Case
Reports . 2017;3(2):151-154.
8. Hayashi H, Kawaguchi T, Horie M. Effect of Flecainide on T-Wave
Alternans in Andersen-Tawil Syndrome. Ann Noninvasive
Electrocardiol . 2014;19(4):383-6.
9. Bökenkamp R, Wilde AA, Schalij MJ, et al. Flecainide for recurrent
malignant ventricular arrhythmias in two siblings with Andersen-Tawil
syndrome. Hear Rhythm . 2007;4(4):508-11.
10. Janson CM, Poelzing S, Shah MJ. Combined inhibition of Na+ and Ca2+
channels: A novel paradigm for the treatment of incessant ventricular
arrhythmias in Andersen-Tawil syndrome. Hear Rhythm .
2014;11(2):318-20.
11. Fernández M, Marín MDR, Fernández-Armenta J, et al. Response to
flecainide test in Andersen-Tawil syndrome with incessant ventricular
tachycardia. PACE - Pacing Clin Electrophysiol .
2018;41(4):429-432.